Homepage
Author:
ABBISKO THERAPEUTICS
Posted Date:
March 31, 2026
Abbisko Therapeutics’ FGFR4 Inhibitor Irpagratinib Granted Orphan Drug Designation by EMA for Hepatocellular Carcinoma
ABBISKO THERAPEUTICS
March 31, 2026
Abbisko Therapeutics’ FGFR2/3 Inhibitor ABSK061 Receives FDA IND Clearance for Achondroplasia in Children
ABBISKO THERAPEUTICS
March 31, 2026
